Elite in Hypophosphatasia (HPP)

Dr. Priya S. Kishnani

Pediatrics
Duke Health Integrated Practice Inc
40 Duke Medicine Cir, 
Durham, NC 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Elite in Hypophosphatasia (HPP)
Duke Health Integrated Practice Inc
40 Duke Medicine Cir, 
Durham, NC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Priya Kishnani is a Pediatrics provider in Durham, North Carolina. Dr. Kishnani is rated as an Elite provider by MediFind in the treatment of Hypophosphatasia (HPP). Her top areas of expertise are Pompe Disease, Glycogen Storage Disease Type 3, Hypophosphatasia (HPP), Glycogen Storage Disease Type 9, and Splenectomy. Dr. Kishnani is currently accepting new patients.

Her clinical research consists of co-authoring 332 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 23 articles in the study of Hypophosphatasia (HPP).

Specialties
Pediatrics
Licenses
Pediatrics in NC
Hospital Affiliations
Duke University Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Piedmont
  • HMO
  • POS
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 3 Less Insurance Carriers -

Locations

DUKE HEALTH INTEGRATED PRACTICE INC
40 Duke Medicine Cir, Durham, NC 27710

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

GBE Deficiency (GSD IV and APBD) Natural History Study
GBE Deficiency (GSD IV and APBD) Natural History Study
Enrollment Status: Recruiting
Publish Date: May 28, 2025
Intervention Type: Other
Developing a Management Approach for Patients With Late-Onset Pompe Disease GAA Variant Identified by Newborn Screening
Developing a Management Approach for Patients With Late-Onset Pompe Disease GAA Variant Identified by Newborn Screening
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other
Immunophenotyping of Patients With MPS II Treated With Enzyme Replacement Therapy
Immunophenotyping of Patients With MPS II Treated With Enzyme Replacement Therapy
Enrollment Status: Terminated
Publish Date: September 19, 2024
An Open-Label, Fixed-Sequence, Ascending-Dose, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Intravenous Infusions of ATB200 Co-Administered With Oral AT2221 in Adult Subjects With Pompe Disease
An Open-Label, Fixed-Sequence, Ascending-Dose, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Intravenous Infusions of ATB200 Co-Administered With Oral AT2221 in Adult Subjects With Pompe Disease
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug
Study Drugs: ATB200, AT2221
Study Phase: Phase 1/Phase 2
The Down Syndrome Clinical Trials Network (DS-CTN) Study of Alzheimer's Disease in Down Syndrome
The Down Syndrome Clinical Trials Network (DS-CTN) Study of Alzheimer's Disease in Down Syndrome
Enrollment Status: Terminated
Publish Date: June 27, 2024
A Multicenter, Multinational, Observational Morquio A Registry Study (MARS)
A Multicenter, Multinational, Observational Morquio A Registry Study (MARS)
Enrollment Status: Completed
Publish Date: March 05, 2024
Intervention Type: Drug
An Open-label, Multicenter, Single-arm, Phase 4 Study of the Effect of Treatment With Velaglucerase Alfa on Bone-related Pathology in Treatment-naïve Patients With Type 1 Gaucher Disease
An Open-label, Multicenter, Single-arm, Phase 4 Study of the Effect of Treatment With Velaglucerase Alfa on Bone-related Pathology in Treatment-naïve Patients With Type 1 Gaucher Disease
Enrollment Status: Completed
Publish Date: February 01, 2022
Intervention Type: Dietary supplement, Drug
Study Phase: Phase 4
A Multicenter, Randomized, Double-Blind, Parallel-Group Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) Enzyme Replacement Therapy Compared With Imiglucerase in Patients With Type I Gaucher Disease
A Multicenter, Randomized, Double-Blind, Parallel-Group Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) Enzyme Replacement Therapy Compared With Imiglucerase in Patients With Type I Gaucher Disease
Enrollment Status: Completed
Publish Date: June 08, 2021
Intervention Type: Biological
Study Phase: Phase 3
A Three-Month, Open-Label, Randomized, Dose-escalation Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of VAL-1221 Versus Myozyme®/Lumizyme® in Patients With Late-Onset GSD-II (Pompe Disease) Followed by Open-Label Treatment With VAL-1221 in All Patients
A Three-Month, Open-Label, Randomized, Dose-escalation Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of VAL-1221 Versus Myozyme®/Lumizyme® in Patients With Late-Onset GSD-II (Pompe Disease) Followed by Open-Label Treatment With VAL-1221 in All Patients
Enrollment Status: Terminated
Publish Date: June 02, 2020
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 3 Switchover Study of the Efficacy and Safety of BMN 701 (GILT-tagged Recombinant Human GAA) and Long-Term Study for Extended Treatment in rhGAA Exposed Subjects With Late-onset Pompe Disease
A Phase 3 Switchover Study of the Efficacy and Safety of BMN 701 (GILT-tagged Recombinant Human GAA) and Long-Term Study for Extended Treatment in rhGAA Exposed Subjects With Late-onset Pompe Disease
Enrollment Status: Terminated
Publish Date: June 14, 2018
Intervention Type: Drug
Study Phase: Phase 3
View 9 Less Clinical Trials

326 Total Publications

In memoriam: Stephen G. Kahler, MD.
In memoriam: Stephen G. Kahler, MD.
Journal: Molecular genetics and metabolism
Published: August 03, 2025
Similar Doctors
Experienced in Hypophosphatasia (HPP)
Dr. Eveline Y. Wu
Allergy and Immunology | Pediatrics | Pediatric Rheumatology
Experienced in Hypophosphatasia (HPP)
Dr. Eveline Y. Wu
Allergy and Immunology | Pediatrics | Pediatric Rheumatology
1301 Central Dr, 
Sanford, NC 
 (39.7 miles away)
919-718-9512
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Eveline Wu is an Allergy and Immunologist and a Pediatrics provider in Sanford, North Carolina. Dr. Wu is rated as an Advanced provider by MediFind in the treatment of Hypophosphatasia (HPP). Her top areas of expertise are Congenital Athymia, Osteomyelitis in Children, Localized Scleroderma, and Multisystem Inflammatory Syndrome in Children (MIS-C). Dr. Wu is currently accepting new patients.

Experienced in Hypophosphatasia (HPP)
Dr. Sara H. Duffus
Pediatric Endocrinology | Pediatrics
Experienced in Hypophosphatasia (HPP)
Dr. Sara H. Duffus
Pediatric Endocrinology | Pediatrics

Unc Physicians Network LLC

1301 Central Dr, 
Sanford, NC 
 (39.7 miles away)
919-718-9512
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Sara Duffus is a Pediatric Endocrinologist and a Pediatrics provider in Sanford, North Carolina. Dr. Duffus is rated as an Experienced provider by MediFind in the treatment of Hypophosphatasia (HPP). Her top areas of expertise are Type 1 Diabetes (T1D), Hypophosphatasia (HPP), Thyroid Cancer, Neonatal Hypothyroidism, and Thyroidectomy. Dr. Duffus is currently accepting new patients.

Experienced in Hypophosphatasia (HPP)
Dr. Ali S. Calikoglu
Pediatric Endocrinology | Pediatrics
Experienced in Hypophosphatasia (HPP)
Dr. Ali S. Calikoglu
Pediatric Endocrinology | Pediatrics
101 Manning Dr, 
Chapel Hill, NC 
 (9.5 miles away)
919-966-4131
Languages Spoken:
English, Turkish
See accepted insurances
Accepting New Patients

Ali Calikoglu is a Pediatric Endocrinologist and a Pediatrics provider in Chapel Hill, North Carolina. Dr. Calikoglu is rated as an Experienced provider by MediFind in the treatment of Hypophosphatasia (HPP). His top areas of expertise are Anorchia, Septo-Optic Dysplasia, Type 1 Diabetes (T1D), and Diabetic Ketoacidosis. Dr. Calikoglu is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kishnani's expertise for a condition
ConditionClose
View All 18 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile